Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Cs4 for Pneumoconiosis Rehabilitation

6 listopada 2026 zaktualizowane przez: Tung Leong FONG

Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract (Cs4) Supplementation in Pneumoconiosis Rehabilitation: a Randomized, Controlled Trial

This clinical trial will test whether a Cordyceps supplement improves lung function. The supplement is called Cordyceps sinensis mycelium Culture extract (Cs4). The study will include adults with pneumoconiosis, a lung disease caused by breathing in mineral dust. Researchers will also assess Cs4 safety.

The main questions are: (1) does Cs4 improve lung function compared with a placebo? (2) what health problems occur while participants take Cs4?

The study will include 84 adults aged 18 to 75 years. Their breathing condition must have been stable for at least three months. The study will take place at the School of Chinese Medicine, The University of Hong Kong.

Researchers will compare Cs4 with a placebo, a look-alike capsule containing no Cs4. Chance will determine which capsules each participant receives. Each participant has an equal chance of joining either group. Participants and researchers who assess them will not know which capsules participants receive.

Participants will: (1) take two capsules of Cs4 or placebo twice daily for 24 weeks; (2) record the capsules they take each day and return unused capsules at study visits; (3) attend clinic visits for breathing tests, a walking test, and blood tests; (4)answer questions about their breathing symptoms and daily life. (5) continue follow-up visits for 12 weeks after finishing the capsules.

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Szacowany)

84

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

  • Nazwa: Yunqing Xun
  • Numer telefonu: +852 5229 5427

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 75 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria: (1) adults aged 18-75 years; (2) diagnosed with pneumoconiosis based on clinical and radiological criteria, including chest X-ray/computed tomography and International Labour Organization (ILO) classification; (3)stable respiratory condition for at least 3 months before enrollment, with no acute exacerbations, hospitalizations, or changes in respiratory medication; (4)able to provide written informed consent.

Exclusion Criteria:

(1) history of chronic respiratory diseases other than pneumoconiosis that may confound FEV1/FVC assessment, such as asthma, bronchiectasis, or interstitial lung disease of other etiologies; (2) known allergy to Cordyceps sinensis or any component of the study supplement; (3) pregnancy or breastfeeding; (4)severe comorbid conditions that could interfere with participation, such as active cancer, decompensated heart failure classified as New York Heart Association (NYHA) Class III-IV, or uncontrolled psychiatric illness; (5) cognitive impairment affecting decision-making capacity.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie podtrzymujące
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Potroić

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Cs4 supplementation

Participants will receive Cordyceps sinensis mycelium culture extract (Cs4) orally at 1.6 g per day, administered as two 0.4 g capsules twice daily for 24 weeks, followed by 12 weeks of follow-up.
Suplement diety: Cordyceps sinensis mycelium culture extract (Cs4)

Cordyceps sinensis Mycelium Culture Extract (Cs4) is a fermented mycelial preparation of Cordyceps sinensis, a fungus used in Traditional Chinese Medicine. It is produced by cultivating and fermenting the mycelium, the vegetative part of the fungus. In this trial, Cs4 is used as a dietary supplement to investigate its effects on lung function and rehabilitation outcomes in adults with pneumoconiosis.
Komparator placebo: Matching placebo

Participants will receive matching placebo orally, administered as two capsules twice daily for 24 weeks, followed by 12 weeks of follow-up. Placebo capsules will contain starch, sucrose, and food-grade colorants and will match Cs4 capsules in size, color, weight, smell, and packaging.
Inny: Matching Placebo (B)

Matching placebo capsules containing starch, sucrose, and food-grade colorants, with no Cs4 extract. The placebo capsules will match the Cs4 capsules in size, color, weight, and smell and will be supplied in identical blister packs to maintain blinding. Participants will take two capsules orally twice daily for 24 weeks.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Forced Expiratory Volume in One Second/ Forced Vital Capacity (FEV1/FVC) ratio
Ramy czasowe: from baseline to week 24

Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) will be measured by trained, blinded assessors using standardized spirometry according to American Thoracic Society/European Respiratory Society standards.
from baseline to week 24

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Forced Expiratory Volume in One Second (FEV1)
Ramy czasowe: Baseline, week 12, week 24, and week 36

Change from baseline in FEV1, measured in liters by spirometry according to American Thoracic Society/European Respiratory Society standards.
Baseline, week 12, week 24, and week 36
Forced Vital Capacity (FVC)
Ramy czasowe: Baseline, week 12, week 24, and week 36

Change from baseline in FVC, measured in liters by spirometry according to American Thoracic Society/European Respiratory Society standards.
Baseline, week 12, week 24, and week 36
Six-Minute Walk Distance (6MWD)
Ramy czasowe: Baseline, week 12, week 24, and week 36

Change from baseline in the total distance walked during the six-minute walk test, measured in meters. A longer distance indicates greater functional exercise capacity.
Baseline, week 12, week 24, and week 36
St. George's Respiratory Questionnaire (SGRQ) Total Score
Ramy czasowe: Baseline, week 12, week 24, and week 36

Change from baseline in SGRQ total score, assessing overall impairment in respiratory health status. Scores range from 0 to 100, with higher scores indicating worse health status.
Baseline, week 12, week 24, and week 36
Modified Medical Research Council (mMRC) Dyspnea Scale Score
Ramy czasowe: Baseline, week 12, week 24, and week 36

Change from baseline in mMRC Dyspnea Scale score, assessing limitations in daily activities caused by breathlessness. Scores range from 0 to 4, with higher scores indicating greater limitation.
Baseline, week 12, week 24, and week 36
Leicester Cough Questionnaire (LCQ) Total Score
Ramy czasowe: Baseline, week 12, week 24, and week 36

Change from baseline in LCQ total score, assessing cough-related quality of life using 19 items across physical, psychological, and social domains. The total score ranges from 3 to 21, with higher scores indicating better quality of life.
Baseline, week 12, week 24, and week 36

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
High-Sensitivity C-Reactive Protein (hs-CRP) Level
Ramy czasowe: Baseline, week 24, and week 36

Change from baseline in blood high-sensitivity C-reactive protein (hs-CRP) concentration, measured using an immunoturbidimetric assay. Change will be calculated separately at week 24 and week 36 by subtracting the baseline concentration from the concentration at each follow-up visit.
Baseline, week 24, and week 36
Interleukin-6 (IL-6) Level
Ramy czasowe: Baseline, week 24, and week 36

Change from baseline in blood IL-6 concentration, measured using a high-sensitivity enzyme-linked immunosorbent assay (ELISA). Change will be calculated separately at week 24 and week 36 by subtracting the baseline concentration from the concentration at each follow-up visit.
Baseline, week 24, and week 36
Malondialdehyde (MDA) Level
Ramy czasowe: Baseline, week 24, and week 36

Change from baseline in blood MDA level, assessed using a thiobarbituric acid reactive substances (TBARS) assay. Change will be calculated separately at week 24 and week 36 by subtracting the baseline value from the value at each follow-up visit.
Baseline, week 24, and week 36
Superoxide Dismutase (SOD) Activity
Ramy czasowe: Baseline, week 24, and week 36

Change from baseline in blood SOD activity, measured using a colorimetric assay based on nitroblue tetrazolium reduction. Change will be calculated separately at week 24 and week 36 by subtracting the baseline activity from the activity at each follow-up visit.
Baseline, week 24, and week 36
Glutathione Peroxidase (GPx) Activity
Ramy czasowe: Baseline, week 24, and week 36

Change from baseline in blood GPx activity, measured using a coupled enzyme assay based on nicotinamide adenine dinucleotide phosphate (NADPH) oxidation. Change will be calculated separately at week 24 and week 36 by subtracting the baseline activity from the activity at each follow-up visit.
Baseline, week 24, and week 36

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Tung Leong FONG

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

2 grudnia 2026

Zakończenie podstawowe (Szacowany)

1 marca 2028

Ukończenie studiów (Szacowany)

1 października 2028

Daty rejestracji na studia

Pierwszy przesłany

29 października 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

6 listopada 2026

Pierwszy wysłany (Rzeczywisty)

12 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

12 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

6 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • UW 26-315

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

De-identified individual participant data underlying the results reported in the primary study publication will be shared, together with a data dictionary. Shared data will include participant characteristics, treatment allocation, lung function measurements, six-minute walk distance, questionnaire scores, biomarker results, and adverse event data used in the published analyses. Direct identifiers and the participant identification linkage file will not be shared. Access will be provided to qualified researchers following approval of a research proposal and execution of a data use agreement. Sharing will be subject to any required institutional review board (IRB) and institutional approvals and must be consistent with participant consent.

Ramy czasowe udostępniania IPD

De-identified individual participant data and the selected supporting documents will be available from publication of the primary study results until five years after study completion.

Kryteria dostępu do udostępniania IPD

De-identified individual participant data underlying the published results, the data dictionary, and the selected supporting documents will be available to qualified researchers upon reasonable request. Requests should be submitted by email to the principal investigator and include a methodologically sound research proposal and statistical analysis plan. The principal investigator will review requests for scientific merit, feasibility, and consistency with participant consent and institutional requirements. Approved researchers may use the data only for analyses specified in the approved proposal. Access will require a signed data use agreement and any necessary IRB and institutional approvals. Data will be provided through secure transfer.

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • SOK ROŚLINNY
  • ANALITYCZNY_KOD

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj